ClinicalTrials.gg
CompletedNCT03215849MAPPLEUpdated Oct 23, 2026

Pacing in Heart Failure With Preserved LVEF

An interventional study of CRT-pacemaker device set to Routine Medical Therapy and CRT-pacemaker device set to Routine Medical Therapy + LVP in Heart Failure, sponsored by Cardiff and Vale University Health Board. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Cardiff and Vale University Health Board · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 482 studies in Heart Failure with a site in United Kingdom — 100 open to participants now, 127 under way, 18 of them phase 3. Heart Failure · United Kingdom.

Enrollment
294th of 314
10 · median 120
Started
2023
with 40 others
No phase
146 of 482
32 open now
Registered
238th of 482
by date

Among the 482 studies in Heart Failure with a site in United Kingdom, this one is the 294th largest by enrollment of the 314 interventional ones that give a count, is one of 41 that started in 2023, is one of 146 with no phase, and was the 238th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

100 of the 482 studies in Heart Failure with a site in United Kingdom are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Heart Failure with a site in United Kingdom, or all of them as a file.
02

Study summary

A random-order cross-over pilot trial of a CE marked device (pacemaker) outside its current intended purposes.

The study will comprise 10 patients. Recruitment of patients will take place from The University Hospital of Wales (Cardiff \& Vale University Health Board [CVUHB]). All patients recruited will have septal flattening during exercise demonstrated using contrast stress (exercise) echocardiography.

All 10 patients will be implanted with a CRT-pacemaker device and will be tested on all three of the following settings on separate visits (with a gap of up to 5 days between visits) in random order:

Routine Medical Therapy Routine Medical Therapy + LVP Routine Medical Therapy + BiVP

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical features consistent with heart failure. All patients will have symptoms of moderate to severe heart failure with (NHYA) classification III or IV symptoms (for at least 3 months).
  2. LV less or equal to 50%, with no evidence of significant valvular disease, no hypertrophic or restrictive cardiomyopathy, and no evidence of pericardial constriction.
  3. Additionally all patients will have demonstrated evidence of septal flattening during exercise using contrast echocardiography.
  4. Adults (over 18 years)
  5. Negative test for Covid during surgical pre-assessment, and adherence to prescribed self-isolation before implantation.
  6. Two weeks or more following final dose of vaccination against coronavirus.

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide .
  2. Enrolment in other clinical studies.
  3. more than 35
  4. Objective evidence of significant lung disease on formal lung function testing
  5. Previous (within three months) or scheduled coronary revascularisation or other cardiac surgery
  6. Acute coronary syndrome (within the previous three months)
  7. History of atrial fibrillation (AF)
  8. Renal insufficiency requiring haemodialysis
  9. less than 6 months
  10. Prosthetic heart valves
  11. Blood coagulation disorders
  12. patients (e.g. AIDS, patients on , cytotoxic drugs, and radiation therapy)
  13. Currently pregnant, or intending to conceive.
  14. Recent positive Covid test (up to 14 days prior to pre-assessment).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Sham comparator
    Routine Medical Therapy

    Routine Medical Therapy

    Device: CRT-pacemaker device set to Routine Medical Therapy

  • Experimental
    Routine Medical Therapy + LVP

    Routine Medical Therapy + LVP

    Device: CRT-pacemaker device set to Routine Medical Therapy + LVP

  • Experimental
    Routine Medical Therapy + BiVP

    Routine Medical Therapy + BiVP

    Device: CRT-pacemaker device set to Routine Medical Therapy + BiVP

Interventions

  • DeviceCRT-pacemaker device set to Routine Medical Therapy

    Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy

  • DeviceCRT-pacemaker device set to Routine Medical Therapy + LVP

    Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP

  • DeviceCRT-pacemaker device set to Routine Medical Therapy + BiVP

    Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP

06

What researchers measure

Primary outcomes

  1. Change in septal radius of curvature (corrected for LV area) between rest and peak exercise on stress echocardiography across the three pacing states.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in LV area between rest and exercise across the three pacing states

    Time frame: 12 weeks

  2. Change in Systolic and Diastolic mechanical Dyssynchrony Assessment on echocardiography across the three pacing states

    Time frame: 12 weeks

  3. Change in rest and exercise E/E' on echocardiography across the three pacing states

    Time frame: 12 weeks

07

Study locations

1 site
  • University Hospital Wales
    Cardiff, Cardiff CF14 4UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2025, 23 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 23 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Mar 2025 → Jul 2025 and completion Mar 2025 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2017
First posted
Jul 12, 2017
StartActual
Jul 20, 2023
Primary completionActual
Jul 3, 2025was Mar 2025
CompletionActual
Sep 3, 2025was Mar 2025
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • University Hospital Wales · Cardiff, United Kingdom
Show 1 removed
  • University Hospital Wales · Cardiff, United Kingdom
Oct 23, 2026
Primary completion
Mar 31, 2025→Jul 3, 2025 (actual)
Oct 23, 2026
Study completion
Mar 31, 2025→Sep 3, 2025 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrolling by invitation→Completed
    1 site added, 1 site removed
    Show site
    • University Hospital Wales · Cardiff, United Kingdom
    Show 1 removed
    • University Hospital Wales · Cardiff, United Kingdom
    Primary completion Mar 31, 2025→Jul 3, 2025 (now actual)
    Study completion Mar 31, 2025→Sep 3, 2025 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03215849
Lead sponsor
Cardiff and Vale University Health Board
Collaborators
Norfolk and Norwich University Hospitals NHS Foundation Trust, Cardiff Metropolitan University
Responsible party
Sponsor
First posted
Jul 12, 2017
Start date
Jul 20, 2023
Primary completion
Jul 3, 2025
Completion
Sep 3, 2025
Last update
Oct 23, 2026

Study contacts

Zaheer Yousef
principal investigator · Cardiff and Vale University Health Board

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion